Equities Analysts Set Expectations for WVE FY2029 Earnings

WAVE Life Sciences Ltd. (NASDAQ:WVE) – HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for WAVE Life Sciences in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst A. Fein now expects that the company will earn $0.61 per share for the year, down from their previous forecast of $0.62. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ FY2030 earnings at $3.66 EPS.

A number of other research firms have also weighed in on WVE. UBS Group set a $32.00 price objective on WAVE Life Sciences in a research report on Tuesday, December 16th. B. Riley Financial lifted their price target on WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Royal Bank Of Canada upgraded shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $9.00 to $27.00 in a research note on Monday, December 8th. Raymond James Financial reissued an “outperform” rating and set a $21.00 price objective on shares of WAVE Life Sciences in a research report on Monday, December 8th. Finally, Wall Street Zen lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, WAVE Life Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

WAVE Life Sciences Stock Performance

WVE stock opened at $13.20 on Wednesday. The firm has a 50 day moving average price of $14.09 and a 200-day moving average price of $10.92. WAVE Life Sciences has a 52-week low of $5.28 and a 52-week high of $21.73. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -10.82 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The business had revenue of $17.25 million for the quarter, compared to the consensus estimate of $15.68 million.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. CWM LLC grew its stake in shares of WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after purchasing an additional 2,086 shares during the period. Smartleaf Asset Management LLC grew its position in WAVE Life Sciences by 645.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after buying an additional 1,942 shares during the period. Bessemer Group Inc. increased its holdings in WAVE Life Sciences by 1,156.3% during the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after buying an additional 9,135 shares during the last quarter. Russell Investments Group Ltd. raised its position in WAVE Life Sciences by 1,441.6% in the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after acquiring an additional 9,284 shares during the period. Finally, Ameritas Investment Partners Inc. raised its position in WAVE Life Sciences by 18.7% in the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after acquiring an additional 1,802 shares during the period. Institutional investors own 89.73% of the company’s stock.

Insider Activity at WAVE Life Sciences

In other news, Director Christian O. Henry sold 93,445 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $14.65, for a total transaction of $1,368,969.25. Following the transaction, the director directly owned 12,700 shares of the company’s stock, valued at $186,055. This represents a 88.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Adrian Rawcliffe sold 42,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.00, for a total value of $630,000.00. Following the completion of the transaction, the director owned 12,700 shares in the company, valued at approximately $190,500. This trade represents a 76.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 948,375 shares of company stock valued at $14,112,151 over the last quarter. 23.98% of the stock is owned by company insiders.

Key WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Late‑breaking oral acceptance for WVE‑006 (RestorAATion‑2) means new clinical data — including results from the 400 mg multidose cohort and 600 mg single‑dose cohort — will be presented at the ATS international conference, creating a near‑term data catalyst that could materially move the stock if results are viewed favorably. Wave Life Sciences Announces Acceptance of Late‑Breaking Oral Presentation on WVE‑006
• Positive Sentiment: HC Wainwright reiterated a Buy and raised near‑term EPS estimates (Q1–Q4 2026 and FY2026 modestly), and keeps a $30 price target — analyst backing can support the stock and attracts momentum investors. The upgrades signal that at least one sell‑side shop expects improving fundamentals ahead. HC Wainwright research (reported by MarketBeat)
• Positive Sentiment: Media coverage noting HC Wainwright’s Buy rating increases visibility; headline coverage can amplify investor reaction to the upgrades and upcoming ATS presentation. WAVE Life Sciences Earns Buy Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright’s long‑range projections are mixed — they trimmed FY2029 slightly but project a sizable positive swing by FY2030. These longer‑horizon forecasts are highly model‑dependent and may not move the stock much until nearer‑term clinical or commercial proof points arrive. HC Wainwright long‑term estimates (reported by MarketBeat)
• Negative Sentiment: Offsetting the positives, WVE remains unprofitable with recent quarterly EPS misses and negative margins; consensus and company guidance still point to continued losses in FY2026, which keeps valuation risk high if upcoming data or execution disappoints.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.